Journal
CARDIOVASCULAR DIABETOLOGY
Volume 17, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12933-018-0788-7
Keywords
Type 2 diabetes; Cardiovascular disease; Silent; Asymptomatic; Unrecognised; Atypical; Screening
Funding
- Boehringer Ingelheim
- medical communication agency Fortis Pharma Communications
Ask authors/readers for more resources
Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be silent' or asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available